Evotec SE (NASDAQ:EVO - Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $4.27, but opened at $4.38. Evotec shares last traded at $4.37, with a volume of 7,638 shares trading hands.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on EVO shares. Royal Bank of Canada reiterated an "outperform" rating on shares of Evotec in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $5.93.
Read Our Latest Stock Report on Evotec
Evotec Price Performance
The business's 50-day moving average is $3.94 and its two-hundred day moving average is $4.11. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.
Institutional Trading of Evotec
Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new stake in Evotec during the 4th quarter worth $27,000. CSS LLC IL purchased a new position in Evotec in the 4th quarter valued at about $50,000. Bank of America Corp DE boosted its position in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in Evotec in the 4th quarter valued at about $166,000. Finally, ABC Arbitrage SA purchased a new position in Evotec in the 1st quarter valued at about $260,000. 5.81% of the stock is owned by hedge funds and other institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
